Department of Biomedical Engineering, University of California, Davis, CA, USA.
Department of Pharmaceutic and Pharmacological Sciences, Laboratory for Viral Vector Technology and Gene Therapy, KU Leuven-University of Leuven, Leuven, Belgium.
Acta Biomater. 2018 Mar 15;69:265-276. doi: 10.1016/j.actbio.2018.01.013. Epub 2018 Feb 2.
Alginate hydrogels are widely used as delivery vehicles due to their ability to encapsulate and release a wide range of cargos in a gentle and biocompatible manner. The release of encapsulated therapeutic cargos can be promoted or stunted by adjusting the hydrogel physiochemical properties. However, the release from such systems is often skewed towards burst-release or lengthy retention. To address this, we hypothesized that the overall magnitude of burst release could be adjusted by combining microgels with distinct properties and release behavior. Microgel suspensions were generated using a process we have termed on-chip polymer blending to yield composite suspensions of a range of microgel formulations. In this manner, we studied how alginate percentage and degradation relate to the release of lentivectors. Whereas changes in alginate percentage had a minimal impact on lentivector release, microgel degradation led to a 3-fold increase, and near complete release, over 10 days. Furthermore, by controlling the amount of degradable alginate present within microgels the relative rate of release can be adjusted. A degradable formulation of microgels was used to deliver vascular endothelial growth factor (VEGF)-encoding lentivectors in the chick chorioallantoic membrane (CAM) assay and yielded a proangiogenic response in comparison to the same lentivectors delivered in suspension. The utility of blended microgel suspensions may provide an especially appealing platform for the delivery of lentivectors or similarly sized therapeutics.
Genetic therapeutics hold considerable potential for the treatment of diseases and disorders including ischemic cardiovascular diseases. To realize this potential, genetic vectors must be precisely and efficiently delivered to targeted regions of the body. However, conventional methods of delivery do not provide sufficient spatial and temporal control. Here, we demonstrate how alginate microgels provide a basis for developing systems for controlled genetic vector release. We adjust the physiochemical properties of alginate for quicker or slower release, and we demonstrate how combining distinct formulations of microgels can tune the release of the overall composite microgel suspension. These composite suspensions are generated using a straightforward and powerful application of droplet microfluidics which allows for the real-time generation of a composite suspension.
海藻酸盐水凝胶因其能够以温和且生物相容的方式封装和释放广泛的载药而被广泛用作递送载体。通过调整水凝胶的物理化学性质,可以促进或抑制封装治疗性载药的释放。然而,此类系统的释放通常偏向于突释或长时间保留。为了解决这个问题,我们假设通过将具有不同性质和释放行为的微凝胶组合在一起,可以调整总体突释的幅度。使用我们称之为芯片上聚合物混合的过程生成微凝胶悬浮液,以生成一系列微凝胶制剂的复合悬浮液。通过这种方式,我们研究了海藻酸盐百分比和降解如何与慢病毒的释放相关。尽管海藻酸盐百分比的变化对慢病毒释放的影响很小,但微凝胶降解导致释放量增加了 3 倍,在 10 天内几乎完全释放。此外,通过控制微凝胶中可降解海藻酸盐的量,可以调节相对释放速率。使用可降解的微凝胶制剂在鸡胚绒毛尿囊膜 (CAM) 测定中递送血管内皮生长因子 (VEGF) 编码慢病毒,并与悬浮液中递送相同慢病毒相比产生了促血管生成反应。混合微凝胶悬浮液的实用性可能为慢病毒或类似大小的治疗药物的递送提供了一个特别有吸引力的平台。
基因治疗在治疗包括缺血性心血管疾病在内的疾病和障碍方面具有很大的潜力。为了实现这一潜力,基因载体必须精确且有效地递送到身体的靶向区域。然而,传统的递送方法不能提供足够的空间和时间控制。在这里,我们展示了海藻酸盐微凝胶如何为开发用于控制基因载体释放的系统提供基础。我们调整了海藻酸盐的物理化学性质,以实现更快或更慢的释放,并且我们展示了如何结合不同配方的微凝胶可以调整整体复合微凝胶悬浮液的释放。这些复合悬浮液是使用简单而强大的液滴微流控技术实时生成的,该技术允许实时生成复合悬浮液。